CTI Biopharma's cancer drug fails late-stage trial, shares tumble

CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending its shares down 17 percent.

from Reuters: Health News https://ift.tt/2NB3irv
via IFTTT